An interventional study of Asthma-PASS and Basic Asthma Management (AM) in Asthma in Children, sponsored by Montefiore Medical Center. Completed at 1 site in United States. Open to participants aged 4 Years to 12 Years. Per ClinicalTrials.gov, last updated 2026-10-30.
Sponsored by Montefiore Medical Center · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Asthma by Montefiore Medical Center — 3 open to participants now, 3 under way, none of them phase 3. Asthma · Montefiore Medical Center.
Among the 17 studies in Asthma by Montefiore Medical Center, this one is the 2nd largest by enrollment of the 16 interventional ones that give a count, is one of 3 that started in 2021, is one of 14 with no phase, and was the 12th registered.
4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.
Browse Asthma studies →3 of the 17 studies in Asthma by Montefiore Medical Center are open now, in 1 country. Recruiting first, the newest first:
Montefiore Medical Center · Sites in United States
Ages 18+
Montefiore Medical Center · Sites in United States
Ages 4–12
Montefiore Medical Center · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 416 Asthma studies recruiting now, 141 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.
This study: 4 Years to 12 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 3 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 452 is above the median of 79 across 3,346 interventional studies indexed under Asthma.
Median enrollment 171 across the 16 interventional studies, 29 across the 1 observational. Of the 14 that completed or were terminated, 4 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
Montefiore Medical Center is the lead sponsor of 417 studies on the registry; 69 are open to participants now.
Of its 89 completed or terminated interventional studies of FDA-regulated products, 77 (87%) have results posted.
1 of the studies in Asthma by Montefiore Medical Center that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07228052Montefiore Medical CenterGiving Asthmatics Intramuscular Steroids for Preventing Return to the Emergency Department | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 17 studies in Asthma by Montefiore Medical Center, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Physical activity (PA) is an important component of asthma management in children. Studies show that PA is associated with decreased severity of asthma symptoms, as well as improved disease control and quality of life. However, urban minority children with asthma face barriers to PA on multiple levels.The goal of this research project is to evaluate whether a multifaceted school-based intervention that addresses key barriers to physical activity reduces asthma morbidity among urban schoolchildren with asthma.
Investigators will conduct a cluster-randomized controlled trial with eligible children with persistent or uncontrolled asthma from 60 Bronx schools. Schools will be randomly assigned to either (1) the Asthma-PASS intervention or an asthma management (AM) comparison group. Both groups will participate in an existing classroom-based daily activity program. Enrollment will occur over 4 consecutive school years with 4-8 schools joining the study each year. The investigators will assess the effectiveness of Asthma-PASS in reducing asthma morbidity and improving PA as well as additional clinical and functional outcomes. The investigators will also identify potential mediators and moderators of the intervention effect. They will evaluate the process of intervention implementation by applying the Reach, Effectiveness, Adoption, Implementation, and Maintenance (RE-AIM) framework. The RE-AIM framework is a public health tool used for planning and evaluating programs to improve translation from research into practice and ensure sustainability in real-world settings.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Collaboration with PCPs to optimize management. Community Health Worker (CHW) to ensure PCP plan is followed. Two asthma education sessions with children/caregivers focusing on self-efficacy and physical activity promotion. Promotion of asthma awareness in school. School personnel training in asthma
Behavioral: Asthma-PASS · Behavioral: Child/Caregiver Education session
Includes two sessions of basic asthma education and PCP notification of child's asthma severity level.
Behavioral: Basic Asthma Management (AM) · Behavioral: Child/Caregiver Education session
The investigator will collaborate with the student's primary care provider (PCP) by sending a letter via facsimile, and/or e-mail to ensure appropriate medications are prescribed or adjusted and rescue medications are available at school. Community Health Workers (CHWs) will follow up with PCPs as needed to provide reminders about prescriptions for controlled medications and to ensure a medication administration form (MAF) is provided to schools to allow rescue medication administration by nurses. CHWs will work with local pharmacies when possible to have prescribed medications delivered to schools and homes. For students without a PCP, families will be referred to one of Montefiore Medical Center's 20 practices throughout the Bronx. For students without medical insurance or who are unable to go to a Montefiore clinic, New York City Department of Education (NYC DOE) physicians who routinely attend NYC schools will provide medical care and prescribe appropriate medications.
PCPs and caregivers will be notified that children in the AM group have persistent/uncontrolled asthma that warrants use of guideline-based preventative medications.
The investigator will provide in-school child asthma education sessions delivered by trained, bilingual (English-Spanish) Community Health Workers (CHWs) using an established manualized protocol from past and current studies designed to improve knowledge and self-efficacy. Each child will receive two 1-on 1, 20-minute developmentally appropriate educational sessions at school 3-4 weeks apart. Sessions will cover: 1) asthma basics, symptoms and triggers; and 2) medications and correct administration technique. Caregivers will be called after each child session to highlight key points reviewed with the child and answer questions.
Symptom Free Days (SFDs)
SFDs will be assessed. Caregivers will report the number of days their child experienced no symptoms of asthma (defined as 24 hours with no coughing, wheezing, chest tightness, or shortness of breath) over the prior 14 day period.
Time frame: Baseline, 3, 6, 9, and 12 months
Physical Activity
Physical activity will be assessed by the number of minutes the child engages in either 'Sedentary,' 'Light,' or 'Moderate-Vigorous' physical activity based on measurements taken using the ActiGraph GT3X+ activity monitor, a small, tri-axial micro-electromechanical system (MEMS) based accelerometer. Measurements will be taken over 7 consecutive days at baseline, 3, 6 and 9 months using the activity monitor. Children will wear the monitor on their waist, secured using an elastic belt. The number of minutes the child is in each level of physical activity will be summarized by study arm.
Time frame: Baseline, 3, 6 and 9 months
Physical Activity - Proportion
The proportion of children who participate in in-class physical activity (PA) will be summarized by study arm. It is hypothesized that a greater proportion of children in Asthma-PASS will participate in in-class PA.
Time frame: Baseline, 3, 6 and 9 months
Physical Activity - Step Counts
Physical activity was also assessed by step count using data obtained from the ActiGraph GT3X+ activity monitor, a small, tri-axial micro-electromechanical system (MEMS) based accelerometer. Measurements will be taken over 7 consecutive days at baseline, 3, 6 and 9 months using the activity monitor. Children will wear the monitor on their waist, secured using an elastic belt. The number of steps the child took is summarized by study arm.
Time frame: Baseline, 3, 6 and 9 months
Pediatric Asthma Caregiver's Quality of Life
Validated caregiver asthma related quality of life survey; 13 items, 7-point scale (ranging from 1-7); higher score indicates less impairment
Time frame: 3-12 months
Childhood Asthma Control Test
asthma control based on symptom frequency; score 0-27; higher score indicates well controlled asthma; score 19 or less indicates uncontrolled asthma.
Time frame: 3-12 months
Adherence
controller medication adherence, score range 0-4; higher scores corresponding to recommended behavior.
Time frame: 3-12 months
Asthma Self-management Questionnaire
caregiver self-management behavior; score range 0-100; higher score indicates more knowledge of self-management
Time frame: 3-12 months
Asthma Knowledge
Caregiver asthma knowledge using sub-scale of Asthma Illness Representation Scale; score range 1-5; higher score represent better knowledge.
Time frame: 3-12 months
Children were subjects in the study. Caregivers had to complete validated surveys in order to collect child-specific outcome measures about their child's asthma. The study was exclusively for children with asthma. Caregivers were not subjects in the study.
| Milestone | Asthma-PASS Intervention | Asthma Management Comparison Group |
|---|---|---|
| Started | 226 | 226 |
| Completed | 204 | 208 |
| Not completed | 22 | 18 |
| Withdrew: Withdrawal by subject | 12 | 11 |
| Withdrew: Lost to follow-up | 10 | 7 |
SFDs will be assessed. Caregivers will report the number of days their child experienced no symptoms of asthma (defined as 24 hours with no coughing, wheezing, chest tightness, or shortness of breath) over the prior 14 day period.
| days | Asthma-PASS Intervention | Asthma Management Comparison Group |
|---|---|---|
| Baseline | 7.57 ± 4.95 | 7.97 ± 4.84 |
| 3 month | 10.69 ± 3.93 | 10.56 ± 4.23 |
| 6 month | 10.98 ± 3.95 | 10.96 ± 4.05 |
| 9 month | 11.79 ± 3.42 | 11.46 ± 3.76 |
| 12 month | 11.50 ± 3.82 | 10.58 ± 4.19 |
Physical activity will be assessed by the number of minutes the child engages in either 'Sedentary,' 'Light,' or 'Moderate-Vigorous' physical activity based on measurements taken using the ActiGraph GT3X+ activity monitor, a small, tri-axial micro-electromechanical system (MEMS) based accelerometer. Measurements will be taken over 7 consecutive days at baseline, 3, 6 and 9 months using the activity monitor. Children will wear the monitor on their waist, secured using an elastic belt. The number of minutes the child is in each level of physical activity will be summarized by study arm.
| minutes | Asthma-PASS Intervention | Asthma Management Comparison Group |
|---|---|---|
| Light - Baseline | 218.83 ± 54.83 | 222.80 ± 54.29 |
| Light - 3 months | 161.64 ± 86.03 | 163.06 ± 90.15 |
| Light - 6 months | 159.49 ± 88.09 | 174.37 ± 92.41 |
| Light - 9 months | 149.40 ± 86.99 | 153.77 ± 90.37 |
| Moderate-Vigorous Baseline | 48.71 ± 26.97 | 48.94 ± 20.51 |
| Moderate-Vigorous 3 months | 54.57 ± 24.62 | 56.49 ± 27.13 |
| Moderate-Vigorous 6 months | 57.65 ± 25.06 | 55.26 ± 24.10 |
| Moderate-Vigorous 9 months | 53.51 ± 25.28 | 53.61 ± 15.87 |
| Sedentary - Baseline | 469.03 ± 94.44 | 460.45 ± 100.42 |
| Sedentary - 3 months | 539.17 ± 118.47 | 527.99 ± 129.62 |
| Sedentary - 6 months | 527.71 ± 112.67 | 529.10 ± 129.43 |
| Sedentary - 9 months | 539.09 ± 124.25 | 523.99 ± 132.45 |
Validated caregiver asthma related quality of life survey; 13 items, 7-point scale (ranging from 1-7); higher score indicates less impairment
Results for this outcome have not been posted.
asthma control based on symptom frequency; score 0-27; higher score indicates well controlled asthma; score 19 or less indicates uncontrolled asthma.
Results for this outcome have not been posted.
controller medication adherence, score range 0-4; higher scores corresponding to recommended behavior.
Results for this outcome have not been posted.
caregiver self-management behavior; score range 0-100; higher score indicates more knowledge of self-management
Results for this outcome have not been posted.
Caregiver asthma knowledge using sub-scale of Asthma Illness Representation Scale; score range 1-5; higher score represent better knowledge.
Results for this outcome have not been posted.
The proportion of children who participate in in-class physical activity (PA) will be summarized by study arm. It is hypothesized that a greater proportion of children in Asthma-PASS will participate in in-class PA.
No measurements were reported for this outcome.
Physical activity was also assessed by step count using data obtained from the ActiGraph GT3X+ activity monitor, a small, tri-axial micro-electromechanical system (MEMS) based accelerometer. Measurements will be taken over 7 consecutive days at baseline, 3, 6 and 9 months using the activity monitor. Children will wear the monitor on their waist, secured using an elastic belt. The number of steps the child took is summarized by study arm.
| number of steps | Asthma-PASS Intervention | Asthma Management Comparison Group |
|---|---|---|
| Baseline | 7168.86 ± 1959.37 | 7335.13 ± 2430.19 |
| 3 months | 7318.86 ± 2393.75 | 7268.40 ± 2361.19 |
| 6 months | 7748.53 ± 2515.24 | 7747.63 ± 2612.81 |
| 9 months | 7084.17 ± 2388.91 | 7089.02 ± 2308.95 |
Collected over 1 year. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Asthma-PASS Intervention | 0/226 (0%) | 10/226 (4.4%) | 63/226 (27.9%) |
| Asthma Management Comparison Group | 0/226 (0%) | 7/226 (3.1%) | 29/226 (12.8%) |
| Event | Asthma-PASS Intervention | Asthma Management Comparison Group |
|---|---|---|
| Hospitalization for asthma or respiratory symptomsRespiratory, thoracic and mediastinal disorders | 10/226 | 7/226 |
| Event | Asthma-PASS Intervention | Asthma Management Comparison Group |
|---|---|---|
| asthma-related symptomsRespiratory, thoracic and mediastinal disorders | 52/226 | 25/226 |
| Viral or other infectionsInfections and infestations | 14/226 | 4/226 |
| Age, Categorical(Participants) | Asthma-PASS Intervention | Asthma Management Comparison Group | Total |
|---|---|---|---|
| <=18 years | 226 | 226 | 452 |
| Between 18 and 65 years | 0 | 0 | 0 |
| >=65 years | 0 | 0 | 0 |
| Age, Continuous(years) | Asthma-PASS Intervention | Asthma Management Comparison Group | Total |
|---|---|---|---|
| Mean | 8.09 ± 1.85 | 7.91 ± 1.95 | 8.00 ± 1.90 |
| Sex: Female, Male(Participants) | Asthma-PASS Intervention | Asthma Management Comparison Group | Total |
|---|---|---|---|
| Female | 93 | 105 | 198 |
| Male | 133 | 121 | 254 |
| Ethnicity (NIH/OMB)(Participants) | Asthma-PASS Intervention | Asthma Management Comparison Group | Total |
|---|---|---|---|
| Hispanic or Latino | 167 | 172 | 339 |
| Not Hispanic or Latino | 59 | 53 | 112 |
| Unknown or Not Reported | 0 | 1 | 1 |
| Race (NIH/OMB)(Participants) | Asthma-PASS Intervention | Asthma Management Comparison Group | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 3 | 4 |
| Asian | 6 | 4 | 10 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 77 | 70 | 147 |
| White | 8 | 17 | 25 |
| More than one race | 18 | 21 | 39 |
| Unknown or Not Reported | 116 | 111 | 227 |
| Region of Enrollment(participants) | Asthma-PASS Intervention | Asthma Management Comparison Group | Total |
|---|---|---|---|
| United States | 226 | 226 | 452 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Feb 2021 to primary completion in Aug 2025, 54 months.
Results were first posted in Oct 2026, 1 year 2 months after primary completion. A results delay was requested in Aug 2026.
Of 601 non-industry interventional studies with no phase under Asthma, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 50. This study's 54 months is above that.
Counting every sponsor, half of 651 studies reached it within 23 months; a quarter within 10 and three quarters within 47.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.